TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01109225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vascular check

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal echography
Study: NCT03471195

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Salivary Cytokine profile
Description: Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.

Intervention type: DIAGNOSTIC_TEST
Intervention: Total Salivary Cytokine profile
Description: Saliva will be collected using the passive drool technique and stored in a deep freezerat-60C.
Study: NCT01553617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)
Description: Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human serum albumin
Description: Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
Study: NCT01560429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient controlled epidural analgesia
Description: Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous epidural analgesia
Description: The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
Study: NCT01137682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: * Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: * Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or~* Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotide LAR 30mg
Description: In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lanreotide ATG 120mg
Description: In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
Study: NCT02362789

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: 150 mg secukinumab in 1 ml solution for subcutaneous injection (pre-filled syringe)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in 1 ml solution for subcutaneous injection (pre-filled syringe)
Study: NCT02684136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suvorexant
Description: suvorexant 20 mg taken before sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo taken before sleep
Study: NCT02926118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycemic load
Description: Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High glycemic load
Description: High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
Study: NCT02066636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT05205213

Intervention type: OTHER
Intervention: Surgical Technique (lateral retromuscular preperitoneal)
Description: Open abdominal wall repair through the previous lateral incision for L3-L4 Incisional hernias
Study: NCT01981447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Lacosamide
Description: Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
Study: NCT03545893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600mg prescription, to be taken 1 tablet as needed every 6 hours for pain.
Study: NCT00878007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent screening and treatment for malaria
Description: All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teacher training on literacy instruction
Description: Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness \& vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
Study: NCT02384629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided PCI with conventional DES (Biomatrix flex stent)
Description: BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI with AXXESS stent
Description: The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)
Description: BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
Study: NCT00561028

Intervention type: OTHER
Intervention: blood sample analysis - mycoplasma and chlamydia antibodies
Description: Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

Intervention type: OTHER
Intervention: blood sample analysis - mycoplasma and chlamydia antibodies
Description: Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

Intervention type: OTHER
Intervention: blood sample analysis - mycoplasma and chlamydia antibodies
Description: Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).

Intervention type: OTHER
Intervention: blood sample analysis - mycoplasma and chlamydia antibodies
Description: Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
Study: NCT00579527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured Thymus Tissue for Implantation (CTTI)
Description: Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
Study: NCT00878007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IST plus literacy instruction programme
Description: Schools will receive both IST and the literacy instruction programme
Study: NCT04218227

Intervention type: BEHAVIORAL
Intervention: Self-hypnosis/self-care group
Description: Self-hypnosis/self-care
Study: NCT04218227

Intervention type: BEHAVIORAL
Intervention: Music/self-care
Description: Music-therapy/self-care

Intervention type: BEHAVIORAL
Intervention: Self-care
Description: Self-care

Intervention type: BEHAVIORAL
Intervention: Psycho-education
Description: Psycho-education

Intervention type: BEHAVIORAL
Intervention: Self-hypnosis/self-care motivation
Description: Motivation to learn self-hypnosis/self-care
Study: NCT03794557

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Water Injection
Description: Inhaled Sterile Water Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: PUL-042 Inhalation Solution
Study: NCT01391390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 10mg/day, 12-week treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg/day, 12-week treatment for TD
Study: NCT02195076

Intervention type: OTHER
Intervention: non-invasive detection of cancer odor
Description: The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).

Intervention type: OTHER
Intervention: non-invasive detection of cancer odor
Description: The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).

Intervention type: OTHER
Intervention: non-invasive detection of cancer odor
Description: The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
Study: NCT02211001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Group
Description: The exercises were applied once a week during eight weeks.
Study: NCT02343991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial ExABlate
Description: MR Guided Focused Ultrasound
Study: NCT01049152

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring (CGM)
Description: CGM allocated one time for 3 days

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring (CGM)
Description: CGM allocated one time for 3 days
Study: NCT00796172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Adherence System (MAS)
Description: Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive usual care from their doctors and written materials on CVD risk factors.
Study: NCT02670395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54416076
Description: JNJ-54416076 suspension will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution will be administered orally.
Study: NCT01643889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (domperidone 10 mg)
Description: 1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (domperidone 10 mg)
Description: 1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
Study: NCT02211001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmented Dynamic Exercises Group
Description: The exercises were applied once a week during eight weeks. once a week for eight weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation
Description: The exercises were applied once a week during eight weeks.
Study: NCT00638313

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given either Placebo or PF-04603629.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04603629
Description: Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
Study: NCT00637507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-frequency Oscillation and Tracheal Gas Insufflation
Description: Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., \>10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 \>150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
Study: NCT00605475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continued on their stable daily dose of metformin throughout the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants continued on their stable daily dose of metformin throughout the study
Study: NCT00775931

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: umbilical cord blood transplantation
Description: Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath-1H
Description: Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Campath-1H
Description: Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total Lymphoid Irradiation
Description: Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
Study: NCT03545893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 Mg Oral Tablet
Description: Oxycodone 5mg Oral Tablet prescription, to be taken 1-2 tablets as needed every 6 hours for pain.
Study: NCT02460679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-589
Description: An immediate release film-coated table at a 250 mg dosage strength will be administered per dose and schedule specified in arm.
Study: NCT03893019

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD20.positive tumor cells
Study: NCT00402493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, brimonidine, latanoprost
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen, brimonidine, latanoprost
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: ibuprofen 200mg
Study: NCT00815828

Intervention type: OTHER
Group type: OTHER
Intervention: Resistance exercises
Description: Resistance exercises program consisting of 08 different exercises.
Study: NCT02880995

Intervention type: DEVICE
Group type: OTHER
Intervention: PET scan
Description: The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Description: The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
Study: NCT01643889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (domperidone 10 mg)
Description: 1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (domperidone 10 mg)
Description: 1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (domperidone 20 mg)
Description: 2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
Study: NCT02880995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinical scale
Description: Patient group should complete clinical scales at baseline and 6 week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 weeks of treatment with amisulpride
Description: The investigators are going to measure striatal dopamine synthesis capacity using \[18 fluorine(F)\]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a \>30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
Study: NCT02644356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online CE/CME course
Description: Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
Study: NCT00625638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System
Description: Phone calls made once daily, each taking about 3-5 minutes to complete.